Thermo Scientific (TMO) - Long-Term Debt to Capital

The daily price action for Thermo Fisher Scientific (TMO) shown on this chart, where the indicator stands at 0.70, confirms the effectiveness of supply chain management through the duplication of key counterparties. The diagnostic systems manufacturer is facing a post-pandemic decline in demand and reduced spending by biotech startups. To optimize logistics and regional maintenance services, the business is actively outsourcing a portion of its production processes to external contractors.

TMO Thermo Scientific Long-Term Debt to Equity (07/04/2022 - 11/01/2026)

Analytical breakdowns for Thermo Fisher Scientific

- market value and analyst target forecast:

Market Chart Thermo Fisher Scientific Inc.|TMO - Analyst Consensus Forecast

- market capitalization indicators:

Market Capitalization Thermo Fisher|TMO - Enterprise Value

- company book value details:

Book Value of One Share Thermo Fisher Scientific|TMO - Company Book Value|Capitalization to Book Value Ratio thermofisher.com|TMO - Aggregate Company Assets

- debt and solvency information:

- earnings and multiples data:

TMO - Net Income

General company analysis:Thermo Fisher Scientific Inc., TMO

This ratio correlates liabilities with a maturity of over one year to total equity, determining the business's degree of financial autonomy and debt load. An analysis of the long-term debt structure relative to equity confirms the stability of Thermo Fisher Scientific (TMO), whose dominance in the diagnostics sector and protected patent portfolio enable the efficient servicing of borrowings through stable, multi-year contracts.

Key competitors

Abbott Labs (ABT) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Capital GEHC|Long-Term Debt to Capital Mettler Toledo Inc (MTD)|Long-Term Debt to Capital WAT (Waters Corporation)|Long-Term Indebtedness to Equity bio-techne.com|BRKR - Long-Term Debt to Equity|AZTA (Azenta Inc) - Long-Term Debt to Capital Ratio|Varex (VREX) - Long-Term Debt to Equity|Long-Term Liabilities to Capital Semler (SMLR)|Long-Term Debt to Equity Butterfly Network, Inc.|mesalabs.com (MLAB) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio QSI (Quantum-Si Incorporated)|Long-Term Loans to Capital Ratio NNOX|Long-Term Debt to Capital QTRX (Quanterix Corp)|Ratio of Long-Term Indebtedness to Capital 908 Devices Corporation (MASS)|CapsoVision Medical - Long-Term Debt to Capital|maxcyte.com (MXCT) - Long-Term Debt to Equity Ratio|RPID (rapidmicrobio.com) - Long-Term Debt to Equity Ratio|Seer Inc - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Hyperfine Corp|Long-Term Debt to Equity Ratio FONAR Corporation Inc (FONR)|Long-Term Debt to Capital DXR|MDAI - Long-Term Liabilities to Capital|Long-Term Debt to Capital VIVS (Organovo Holdings, Inc.)|ACON: Long-Term Debt to Capital Ratio|Akoya - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Cesca Therapeutics THMO|TLIS: Long-Term Debt to Capital|Long-Term Debt to Equity Ratio t2biosystems.com